Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Aged over 18 years on the day of inclusion~* Informed consent form signed~* Able to attend all scheduled visits and to comply with all trial procedures~* For a woman, inability to bear a child or negative urine pregnancy test~* For a woman of child-bearing potential, use of an effective method of contraception or abstinence for at least 4 weeks prior and at least 4 weeks after to each vaccination.~Exclusion Criteria :~* Systemic hypersensitivity to any component of the vaccine or a life-threatening reaction after previous administration of a vaccine containing the same substances~* Febrile illness (oral temperature ≥ 37.5°C) on the day of inclusion~* Breast-feeding~* Previous vaccination with an avian flu vaccine~* Participation in a clinical trial (drug, device, or medical procedure) within 4 weeks prior to the first vaccination~* Planned participation in another clinical trial during the present trial period~* Congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months or long-term systemic corticosteroid therapy~* Chronic illness that could interfere with trial conduct or completion (e.g. cardiac, renal, diabetes, or auto-immune disorders)~* Current alcohol or drug abuse that may interfere with the subject's ability to comply with trial procedures~* Receipt of blood or blood-derived products within the past 3 months~* Any vaccination within 4 weeks prior to the first trial vaccination~* Vaccination planned within 4 weeks after any trial vaccination~* Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination~* Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Study Group 1 (Type: EXPERIMENTAL): Vaccine with adjuvant
- Study Group 2 (Type: EXPERIMENTAL): Vaccine without adjuvant

Based on this trial design, predict the completion outcome and termination type (if applicable).